Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Signature Scents: A Manual for Outstanding Fragrances - 2France will build a new aircraft carrier as it increases defense spending
- 3The Most Compelling Innovation Advancements Somewhat recently
- 4US bishops officially ban gender-affirming care at Catholic hospitals
- 5The most effective method to Pick the Right Teeth Substitution Choice for You
- I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- 10 Famous Frozen yogurt Flavors All over The Planet
- Surveys of Music Collections by Film Stars
- The Best Web-based Courses for Expertise Improvement
- The Response to Self-improvement: Embracing a Development Outlook
- Support Your Body: A Manual for Smart dieting and Sustenance
